What is Solu Therapeutics?
Solu Therapeutics operates as a specialized clinical-stage biotechnology firm, established in May 2023 following the acquisition of an exclusive license to the CyTAC platform from GSK. The company is primarily focused on the development of advanced therapeutic modalities, with its lead program currently undergoing Phase 1 clinical trials targeting chronic myelomonocytic leukemia. Beyond its primary oncology focus, Solu Therapeutics is actively advancing a diverse portfolio of CyTAC and TicTAC programs, positioning itself as a high-growth entity within the precision medicine sector. The firm leverages sophisticated scientific frameworks to address significant medical challenges, aiming to translate groundbreaking research into viable clinical candidates that offer improved patient outcomes.
How much funding has Solu Therapeutics raised?
Solu Therapeutics has raised a total of $72M across 2 funding rounds:
Angel/Seed
$31M
Series A
$41M
Angel/Seed (2023): $31M with participation from Santé Ventures, Astellas Venture Management, and Longwood Fund
Series A (2025): $41M led by DCVC Management, Pappas Capital, and Eli Lilly
Key Investors in Solu Therapeutics
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, focusing on leveraging artificial intelligence to unlock potential across biotechnology and other sectors.
Pappas Capital
Pappas Capital is a specialized investment firm focused on the research and development industry, providing strategic backing to innovative life sciences companies.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, and commercialization of prescription medicines, with a strong focus on oncology and immunology.
What's next for Solu Therapeutics?
With the successful closure of this major strategic investment, Solu Therapeutics is poised to enter a critical phase of operational scaling. The capital will be directed toward the acceleration of its lead clinical program and the maturation of its broader pipeline of development candidates. Strategic priorities include the expansion of clinical trial infrastructure and the continued refinement of the CyTAC and TicTAC platforms to ensure long-term competitive differentiation. As the company moves deeper into the clinical development lifecycle, it remains focused on achieving key regulatory milestones and establishing itself as a leader in the next generation of targeted therapeutic interventions.
See full Solu Therapeutics company page
